
    
      Pediatric patients with partial onset epilepsy enrolled in a pharmacokinetic study of OXC XR
      were allowed to continue treatment with the investigational drug in this extensi√≥n study. The
      primary interest was in assessing the safety of treatment with OXC XR over a period of
      months.
    
  